About unite2cure

Unite2Cure is a network of groups and individuals from across Europe, which is calling for better treatment and better access to treatment for children and young people with cancer. The movement, which is parent-led, aims to unite parents/carers, survivors, not for profit organisations, health professionals, researchers and other industry experts in a campaign to save more young lives.

A Response from the Commissioner to the Golden Letters

In May, the Unite2Cure team headed to Brussels to meet with the Health Commisioner Vytenis Andriukaitis. Patricia Blanc, Chris Copland, and Anne Goeres, our delegates from Unite2cure informed the Health Commissioner as to the importance of the Paediatric Regulation, explained where problems have been identified with this regulation in relation to childhood cancer and why change is necessary .

This very productive meeting was also the opportunity to give the Commissioner 200 golden letters from parents and organizations across Europe: together we are stronger!
Yesterday, we received the following letter by post, in reply from the Commissioner.

Time for Change

There have been many incredible advances in the treatment of adult cancers in the past 10 years, but childhood cancer is losing out for many reasons, including the opportunity for industry to apply for waivers in the drug development process. Investigating new agents in children and adolescents is particularly difficult as their numbers are few, studies are costly and outcomes are not guaranteed. This leads to long delays for companies who answer to shareholders, and so sadly a waiver to avoid having to test efficacy in children is the attractive option for many. The bottom line is that children are often sidestepped in the drug development process because of financial challenges.

It is a well-known fact that most children diagnosed with cancer are treated with chemotherapy drugs which are over 30 years old. If we continue to do this, then current survival rates for the most resistant cancers are unlikely to change, the prospect for cure at relapse remains low, and the toxicities (both acute and long-term) will remain unchanged. By ignoring these issues, we are failing our children. Cancer is the number one cause for death by disease in children and adolescents, but in the adult world it is no longer recognised as the automatic death sentence that it once was. Childhood cancer is genetically a much simpler disease, with lower molecular mutation rates. Children and adolescents also have substantially less co-morbidities given that they have exposed their bodies to fewer toxins in their short lives. All these elements point towards the fact that childhood cancer should be addressed in a much more positive and productive way, which is likely to lead to much greater curative rates than are currently being achieved.

Developing new drugs specifically for children will address many of these issues, but another key element to consider is prioritisation. Although 35,000 children and adolescents are diagnosed with cancer each year in Europe, when this number is attributed to individual diseases and disease sub-categories, the numbers of children and young people in each classification are few. This makes prioritising drug development another key issue, as only the most promising compounds and technologies should be brought to the fore for testing when it comes to these very small populations. Children are precious, and should be treated as such in every regard, including childhood cancer research.

Many parents and charity advocates are extremely knowledgeable on this topic, and have spent years campaigning to bring these issues to light. Unite2Cure is uniting these highly informed people and groups to gather momentum to bring one voice to the European Commission in asking for change to regulation to address these core issues. We recognise that difficulties exist for other stakeholders, but we believe many of these can be overcome by making small but strategic changes to the European Paediatric Medicines Regulation.

Parents who have lost their children to cancer, parents who live in fear of relapse and nurse their children through long term side effects, and charities supporting these desperate families all recognise the need for change and see an opportunity for it to happen. Academics understand the limitations of the current regulation and research landscape. Paediatric oncologists state that they don’t want to be the generation who simply administered drugs to maintain this current curative plateau. Surely those highly skilled, highly paid individuals working within drug development grasp these issues and are keen to change the future of many children diagnosed with this devastating disease?

If only it was considered a good return on investment, then this might be the case.

Show your support by signing our petition.

Leona Knox, Unite2Cure

Making better use of known drugs in treating children with cancer

Given the mountain we still have to climb when it comes to treating childhood cancers, it seems wise to explore all possible paths to new treatments.

Drug development is notoriously risky and expensive. This creates a formidable barrier to the introduction of new medicines for children with cancer as the pharmaceutical industry prefers to invest in the development of drugs for the much larger adult cancer population, which holds the potential to repay for the heavy investment and risk. With very few exceptions, specific drugs for children with cancers are not developed and the only hope for sick children is that at some point some of these “adult” drugs will be tested and eventually used in children.

This is far from ideal as children and adolescents with cancer do not have the time to wait. New treatment options that are more effective and safer are urgently needed. While we at U2C are busy working on introducing more effective incentives for companies to develop new medicines for childhood cancer, there are some possible approaches that may bypass the above mentioned hurdle and may be championed by parents’ organisations.

These approaches include drug repurposing and metronomics.

Drug Repurposing, sometimes also called drug repositioning, is the re-use of an existing drug for a new disease. Very often a drug is developed to treat one illness and it is later discovered that it can treat another as well. In the case of cancer, there is evidence that a range of non-cancer drugs may also have anti-cancer effects which may be clinically useful. These drugs, many of them commonly available as generics, are cheap and have low toxicity as well as decades of clinical use for their original uses. While there is a range of evidence to support the anticancer effects of these non-cancer drugs, including some antibiotics and antifungals, there is a need to develop and run clinical trials to put the anticancer effects to the test in the same way as we do with other potential cancer drugs. However, because these drugs are generic there are no commercial incentives to run expensive clinical trials or to license the drugs for new uses if the trials succeed. Therefore, in addition to medical innovation there is also a need for financial innovation to overcome the regulatory barriers to change. Another potential advantage of this approach is that very often these repurposed drugs have been used already in children and adolescent for the treatment of other disease, therefore we would have confidence on the safety of these “old’ drugs in the treatment of children with cancer. This is not a trivial benefit in view of the well-established toxicity of currently used cytotoxic agents.

There are many examples of successful repurposing already. Methotrexate, one of the first drugs developed to treat childhood cancer, is now being used to treat arthritis. Propranolol, used to treat high blood pressure in adults, is now used to treat infantile hemangioma, a disfiguring and sometimes dangerous benign tumour in babies and toddlers. Thalidomide, a drug notorious for causing birth defects when used to treat morning sickness is now being used to treat leprosy and multiple myeloma. This is the only successful example of repurposing a non-cancer drug in oncology, but there is evidence that many more drugs have the potential to do the same.

Metronomics is another approach to drug development that has the potential to impact childhood cancers. Conventional chemotherapy remains the mainstay of treatment in both adult and childhood cancers. It is normally delivered at high doses and is associated with a range of side effects including hair loss, nausea and vomiting and neutropenia (increasing the risk of infection). However, many of these very toxic drugs also show signs of anticancer activity when used at very low doses. Using the drugs at these low doses means that the side effects are minimal and that there is no need for treatment breaks for the body to recover – mostly the drugs are given orally and every day (hence the term metronomic chemotherapy).

In contrast to high dose chemotherapy, metronomic chemotherapy does not cause neutropenia and in fact the evidence suggests that it can boost the anticancer activity of the immune system. The other main action of metronomic chemotherapy is to control the blood supply to the tumour, cutting off the nutrients and oxygen that tumours need to survive. While there have been many clinical trials of metronomic chemotherapy in a wide range of cancers, including some very hard to treat cancers, there is a need for large definitive trials in pediatric cancers. As with drug repurposing the challenges are not just medical but also financial as many of the drugs suitable for metronomics are old generic chemotherapy agents such as cyclophosphamide and methotrexate.

Drug re-purposing and metronomics are just two example of innovative approaches for the development of new treatments for children with cancer that hold the potential to deliver quicker benefit to patients. If you want to know more and hear about some examples of ongoing projects in the childhood cancer area please do not hesitate to contact us.

Cesare Spadoni
cspadoni@apoddfoundation.org
Pan Pantziarka
anticancer.org.uk@gmail.com

 

 

image

Ashburn TT., Thor KB. 2004. Drug repositioning: identifying and developing new uses for existing drugs. Nature reviews. Drug discovery 3:673–683.

A letter to the Commissioner

The Unite2Cure team has composed the following letter, which has been sent to Mr. Andriukaitis, Health and Food Safety Commissioner, European Commission.

Dear Mr Andriukaitis,

We are writing regarding your reply to the letter (dated 10 November) in which MEPs Glenis Wilmott and Françoise Grossetête, draw attention to the failure of European legislation to address the needs of children with cancer.

We appreciate the time you took to review this issue but we strongly feel the need to respond to some of your comments, which in our view do not paint a realistic picture of childhood cancer drug development and, above all, fail to recognize the urgent needs of these young patients.

We all know that the development of new drugs, not just anti-cancer drugs, is a very challenging and risky endeavor and that, ultimately, it is dependent on research and development efforts that cannot be dependent upon legislative measures.  We are also well aware that there are legislative tools, such as Orphan Drug legislation and the Paediatric Medicine Regulation that seek to promote, in one way or another, the development of new medicines for children. The point that should be clear by now is that these measures have a limited impact on childhood cancer drug development and this is the specific problem we would like to address. Just looking at the big picture without analyzing the details will not lead us anywhere.

Orphan drug incentives have been around since the early 80s in the US and were introduced a little later in Europe[1]. It is now crystal clear that these incentives are not powerful enough to stimulate the development of new drugs for childhood cancer. If we look at the US experience, where more solid drug approval records are available, we see that over the past 20 years a total of 180 drugs were approved for the treatment of cancer in adults. During the same time only 3 were approved specifically to treat cancer in children[2]. The record within the EU is even more dismal.

The current incentives provided by Orphan Drug Legislation are sufficiently powerful to support development of drugs for other rare conditions in children. However, for scientific and financial reasons, they fail to meet the needs of childhood cancer. These are very complex diseases to tackle and oncology drug development has on average the highest failure rate[3]. On the other hand, rare genetic diseases are often more treatable because the pathology is driven by one or very few specific genetic drivers. This makes drug development relatively less risky. In economic terms, the tendency of these diseases to become chronic when treated increases the revenue potential of any new drug, which is also likely to be prescribed at a premium price. This financial return is harder to achieve with a paediatric cancer drug as the treatment times are generally shorter and the drugs are unlikely to qualify for premium price, particularly if the same drug is used in more common, adult cancers.

If the Orphan Drug Legislation incentives do not work for childhood cancer drug development, it is equally clear by now that the obligations and incentives envisaged in the Paediatric Medicine Regulation (PMR) do not work either and do not have any meaningful impact on the development of new drugs for children with cancer. Whereas the PMR has indeed stimulated an increase in R&D investment in many paediatric areas, it has failed to make an impact on childhood cancer.

This is not a matter of parental opinion. This is the unanimous conclusion of all key paediatric oncology stakeholders in the 2012 five-year review of the PMR[4] and it is a conclusion that is supported by the very same data you produced to demonstrate impact of this legislation.

Let us be more specific.

As pointed out by Ms Wilmott and Ms Grossetête, up to 6000 children and adolescents die of cancer every year in Europe. We have made some progress in the treatment of certain cancers such as some forms of blood cancers (e.g. lymphomas, leukaemia). However, in a number of high risk cancers that are very specific to children and adolescents (cancers such as neuroblastoma, bone cancers such as Ewing’s Sarcoma and aggressive brain cancers in general), we have not seen any significant therapeutic improvement over the past two decades. These are diseases that take the biggest toll in terms of young patients’ lives on a yearly basis. These are the diseases for which new drug development is the most urgently needed.

Yet, these cancers are largely neglected by industry. In addition, the current legislation allows for waivers even when the science suggests a potential use of certain investigational drugs in specific childhood cancers on the basis of a common mechanism of action. In other words, we are missing opportunities to study compounds that may bring benefit to patients.

You quote some figures provided by EMA experts. The problem with this is that these are just numbers if they are not interpreted and analysed in the right context.  You rightly state that more than 80 paediatric investigation plans (PIPs) have been agreed by the EMA Paediatric Committee. The exact number is actually 81 on the EMA website (accessed Jan 5, 2016 ). Actually only 10 of these positive decisions targeted at least one of those high risk cancers that primarily affect children, a mere 12% of the total study number.  

It is true that a number of studies (16) involved haematological malignancies that do indeed frequently occur in children with cancer but for these diseases we generally already have some valid therapeutic alternatives, unlike for the above mentioned solid cancers. Furthermore, to put things in perspective, the biggest group (17 studies) is made up of studies that do not target cancer but, rather, side effects such as nausea, vomiting, anemia etc. When you consider these details the overall impact is less impressive.

Therefore, it is fair to say that these studies largely fail to address the most urgent need for the paediatric oncology community, which is the development of new drugs for the most aggressive cancers, those which cause the highest number of deaths among children and adolescents.

You mentioned that 5 drugs with a paediatric indication have been approved for children since the PMR was implemented, drawing the conclusion that it is very likely that these programmes would not have been conducted without the PMR. It is not clear which drugs you are referring to but, in any case, we would argue that the data does not support your conclusion.

As far as we know, 9 anti-cancer drugs have been approved for paediatric use since 2007[6]. These are the following (target disease and date of EMA approval in brackets):

nelarabine (2007) *

imatinib (CML, 2009) * A

mifamurtide (OS, 2009) *

mercaptopurine (ALL, 2009) *

everolimus (SEGA, 2011) PIP # A

mercaptopurine (ALL, 2012) * F

imatinib (ALL, 2013) PIP A

dinutuximab (NBL, 2015) PIP

asparaginase (ALL, 2015) PIP

* = did not fall under paediatric regulation (e.g. before regulation came into force or well-established use)

# = anti-neoplastic medicine (concerned neoplasm is not a cancer)

+ = nationally authorised in certain Member States

F = new paediatric pharmaceutical form

PIP = based on studies in an agreed PIP

A = paediatric use was granted only after authorisation was granted for adult use

 

As shown by the above, only a few of these drugs can claim to be the direct result of the PMR. With the exception of Dinutuximab, none of the drugs above have been specifically developed to treat a form of childhood cancer.

We do not see how the data above can support the conclusion that the PMR has had any significant impact on childhood cancer drug development. The figures become also less impressive when taken in the context of global oncology drug development in general. It is estimated that every year approximately 100 to 150 new investigational drugs begin clinical testing and that any point in time there are up to 800-900 anti-cancer compounds in clinical evaluation[7].  It is clear that not enough drugs are developed for children and adolescents. In our view, the approval record of paediatric cancer drugs suggests that this is just “baseline” activity of industry completely unaffected by the current legislation.

The EMA figures clearly show that, basically, no drugs are being developed for the high risk childhood cancers and that companies tend to delay paediatric development as much as possible, as it is regarded as a hurdle on the path of adult development. As you rightly note, the legislation is intended to encourage the development of drugs for children without delaying adult development.  However, it was concluded in the 5 year –review published in 2013 that there is no evidence of a slowdown in adult drug development. On the other hand, the negative impact of waivers and deferrals on patients’ lives should not be underestimated.

While it is important to recognize that sometime a delay is indeed recommended in order to evaluate product safety in adults, we must also understand that whenever the paediatric development of a drug is waived or deferred for whatever reasons, there might be a heavy price to pay in terms of missed opportunities for patients. There have been examples of drugs that have been initially granted waivers or had paediatric development delayed only to recognize a few years down the line that the compound is highly beneficial to children.  The targeted drug Imatinib was first approved for adults in 2001 for the treatment of a specific genetic subtype of chronic myeloid leukaemia (CML) and later for acute lymphoblastic leukaemia (ALL). The same drug was not approved for the treatment of ALL in children before 2013.  Meanwhile, academic sponsored-trials in the US demonstrated a dramatic effect resulting in greatly enhanced survival rates, from 35% up to approximately 80%l[8]. Surely we don’t need to explain that many more children could have been cured had the drug been made available earlier.

The implications of all these facts and figures are very clear.

We may have different views on how to reform the PMR and to what extent we may want to enforce stricter obligations and/or offer more attractive incentives.  But one point should be clear by now. The PMR, as it stands, does not address the needs of children and adolescents with cancer. All key stakeholders and key opinion leaders agree upon this point. This was the conclusion of the Europe Society of Paediatric Oncology (SIOPE) in 2012 after the first review of the PMR requested by EMA[9]. This is opinion of countless patients/parents’ organisations united under the Unite2Cure umbrella[10]If we simply acknowledge the problem we can start to have a sensible and constructive discussion with all stakeholders, with the probability of enacting reforms that will make sense for all parties.

If, by contrast, we do not acknowledge this fact and insist we need more time to judge, we are, indirectly, harming all those young patients that will be diagnosed with cancer in the near future. Time is exactly what children and adolescents with cancer do not have.

Those of us whose children have been and are being impacted by cancer know first-hand the urgent need to tackle the disease which causes the highest number of deaths amongst our children in Europe. We want our political representatives and European legislators to recognize this need for urgency and to facilitate changes that will give children diagnosed with cancer a better chance of life.

As Ms Wilmott and Ms Grossetête clearly wrote, the time for action is NOW.

We very much look forward to your thoughts and comments.

Kind regards,
The Unite2Cure Team

 

Founding Members

Nicole Scobie, Zoé4life (Switzerland)
Debbie Binner, Create for Chloe and trustee of aPODD (UK)
Patricia Blanc, Imagine for Margo children without cancer (France)
Anne Goeres, Fondatioun Kriibskrank Kanner (Luxembourg)
Danielle Horton Taylor, PORT and Consumer Representative National Cancer Research Institute (UK)
Anita Kienesberger, Österreichische Kinder-Krebs-Hilfe (Austria)
Angela Polanco, Bethany’s Wish (UK)
Cesare Spadoni, aPODD (UK)
Chris Copland, Consumer Representative, National Cancer Research Institute (UK)
Gerlind Bode, Board Member of Förderkreis Bonn e.V. (Germany)
Kevin and Karen Capel, Christopher’s Smile (UK)

[1] http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4204542/

[2] http://www.fda.gov/; https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology

[3] http://www.nature.com/nbt/journal/v32/n1/full/nbt.2786.html

[4] http://ec.europa.eu/health/human-use/paediatric-medicines/developments/2013_paediatric_pc_en.htm

[5] http://www.ema.europa.eu/ema/index.jsp?curl=pages%2Fmedicines%2Flanding%2Fpip_search.jsp&mid=WC0b01ac058001d129&searchkwByEnter=false&alreadyLoaded=true&isNewQuery=true&keyword=Enter+keywords&searchType=Invented+name&taxonomyPath=&treeNumber=&currentCategory=Oncology

[6] EMA Officer – Personal Communication

[7] On-Kos Consulting – Personal Communication http://www.on-kos.it/

[8] http://jco.ascopubs.org/content/27/31/5175.full

[9] http://ec.europa.eu/health/files/paediatrics/2013_pc_paediatrics/37-siop.pdf

[10] https://unite2cure.org/

A call for concrete action

Unite2Cure is delighted to be a partner in a multi-stakeholder call for concrete action to improve the availability of effective innovative cancer medicines for children and adolescents with cancer.  The call was launched at the event ‘Development of Paediatric Cancer Medicines – Speeding up Innovation, Saving Lives’. Although cancer remains the first cause of death by disease beyond one year of age; very few new medicines reach children and adolescents with cancer in Europe, even after the implementation of the 2007 EU Paediatric Medicine Regulation.

The proposals were presented at a yearly event by The European Society for Paediactric Oncology (SIOPE) www.siope.eu/activities  to mark International Childhood Cancer Day (15th February 2016).  The aim of the proposals is to suggest solutions to the current lack of drug development for children and teenagers with cancer.

©SIOPE & Joke Emmerechts photography

Chris Copland, one of Unite2Cure’s founding members, and Consumer Representative, National Cancer Research Institute (UK)

 

We are proud that Christopher Copland (UK), one of the founding members of Unite2Cure, spoke at the event of the urgent need to accelerate drug development for these young people.  He called for more attractive rewards for the pharmaceutical industry to develop innovative drugs for children’s malignancies; following the example of the “Creating Hope Act” system in the USA.

Also there was Unite2Cure partner Anne Goeres (Lu) from the Foundation Kriibskrank Kanner.  She stressed the need to join forces with the rare diseases’ community in advocating better treatments.

©SIOPE & Joke Emmerechts photography

Anne Goeres, one of Unite2Cure’s founding members, Fondatioun Kriibskrank Kanner (Lu)

 

 

Member of the European Parliament Glenis Willmott (S&D, UK), a strenuous supporter of the causes of the childhood cancer community over the past years, hosted and introduced the event. Martin Schrappe (DE), President of SIOPE, presented the ‘SIOPE-ITCC-CDDF Multistakeholder Platform’, created in 2013 by representatives of parent/patient advocates, academia, industry and regulators. The Platform works on proposals to increase innovative drug development that are regularly presented to decision-makers during a series of Paediatric Oncology Conferences, the last of which led to three stakeholders’ joint proposals to improve the effectiveness of the Regulation’s implementation.

Unite2Cure is a parent-led movement which aims to mobilise the parent/child/NGO voice to push urgently for better treatments and better access to treatments for young people with cancer.  The  current status quo means that:

– 6,000 children and teenagers die of cancer in Europe each year

– less than 1 in 10 of children with relapsed terminal cancer has access to  innovative new treatments.

– whilst progress has been made; many high risk cancers have not seen any therapeutic improvements in the past two decades

– childhood/teen cancers are largely neglected by industry

– current legislation allows waivers; even when science suggests a potential use

– EMA figures show that basically no drugs are developed for the high risk cancers.

If you care – join our discussion; sign our petition, or talk to us nicole@scobie.com   or deborahjanebinner@gmail.com

Time to accelerate

 

Last week several parents, survivors and patient advocates from Europe and the U.S. united in Brussels for the CDDF-ITCC-SIOPE 4th Paediatric Oncology Conference. The title of this year’s meeting was: Accelerating the Development of New Oncology Drugs for Children and Adolescents.

Debbie Binner of Create for Chloë presented the Unite2Cure movement along with Chris Copland, Consumer Representative, National Cancer Research Institute and Nicole Scobie of  Zoé4life. The presentation was very well received, and as Debbie explained later, the conference ended with a general sense of possibility. “Believe me the first CDDF conference was very very different to this one.  Us parents were fighting to be heard – and now there is such a sense of integration and collaboration and a real sense that we are making some progress.  Although obviously there is a long long way to go.”

 

A few key moments:

12562714_10153851277421800_891955760_o

Patricia Blanc presents

Patricia Blanc of Imagine for Margo‘s presentation on new incentives for pharmaceutical companies to invest in paediatric research was brilliant. Her voice is powerful and the work of her Working Group on this project has moved forward with an action plan. Nancy Goodman of KidsVCancer gave an excellent and comprehensive update on the successful US Creating Hope Act regulation.

Angela Polanco of Bethany’s Wish participated actively in a round table discussion on the new incentives topic, and explained that parents want to be involved from the very beginning in the process of approving paediatric investigation plans and participating in the development of clinical trials.

 

Chris Copland spoke up several times, passionately advocating for change to the Paediatric Medicines Regulation. He and Anne will be speaking on behalf of Unite2Cure today, January 27th in front of the European Parliament at an event organized by SIOPE in honour of International Childhood Cancer Awareness Day. This influential awareness raising meeting entitled ‘Speeding up Innovation, Saving Lives’ will be hosted by  MEP Ms Glenis Willmott. The goal is to address the development of paediatric cancer medicines and an enabling legislative and regulatory environment. In plain words: we are asking for very specific changes to the regulations NOW.

 

Leona Knox, of Solving Kids Cancer-Europe spoke with a powerful message, summarizing her feelings about the 2 day conference. “I am one of the parents here who won’t be going home to my son tonight. Oscar died, not because he had cancer, but because he ran out of treatment options. We parents have come here on our own time, and have worked so hard to make sure we understand what you have presented.” She told the audience of mostly pharmaceutical company representatives, pediatric oncologists and regulators. “Our goal is to save kids’ lives. We are working so hard to come up with solutions, and I just want to ask you all, to please help us fix this, whatever it takes.”

Both Samantha Schoolar of Bethany’s Wish and Jaap den Hartogh of VOKK spoke very clearly about the long term side effects survivors of childhood cancer experience and the need to speed up better treatments as well as research into late effects. “A real cure means being part of society once more,” explained Jaap, who called for new, better, and less toxic medicines as well as access to long-term follow up care for every survivor in Europe.

 

It was inspiring to hear Peter Adamson, the Chair of the Children’s Oncology Group stand up to remind the audience that the title of this conference was “Accelerating the Development of New Oncology Drugs for Children and Adolescents”, and that, having attended these conferences for the past several years, he did not want to just have the same conversations as every year. It was time to actually accelerate.

 

Gilles Vassal, past president of SIOPE and Director of Clinical and Translational Research at the Institut de Cancérologie Gustave-Roussy made a clear call to “change the mindset“.

_97A8684

Change the mindset!

The summary of the decisions and plans as a result of the conference are, briefly:

-a strengthening of the  CDDF-ENCCA – ITCC-SIOPE platform with terms of reference, a website and a new name (to be announced!).

-position papers will be created by Working Group 1 on the issues of adolescent inclusion in adult phase one trials and on mechanism of action as a determinant for paediatric investigation plan requirements.

-a position paper is being drafted on Working Group 2’s proposals for new incentives

-a white paper will be put together by Working Group 3 regarding long term follow up for children receiving new drugs. This group met immediately after the conference to continue preparing this document.

Gilles Vassal emphasized that parents and survivors must continue to advocate for change for all of these plans to happen.

He ended the conference with one sentence, that summarizes the event, “We are even stronger if we work together.”

2016-01-21 17.33.49

The view over Brussels on the flight home

 

 

 

 

World’s Children Raise their Voices for Childhood Cancer in New Single

raiseyourvoice

Every day 700 children are diagnosed with cancer. It’s time to raise our voices.

Some of the most famous singing kids on YouTube are forming a supergroup to raise awareness about childhood cancer. And the best part? The children of the world are invited to join in!

At child4child.com kids can sing and record the chorus of the song, which will then be released on Feb. 15th, 2016—International Childhood Cancer Day. The song “We Are One” has been created by Christophe Beck, the composer for Disney’s smash hit Frozen.

Childhood Cancer International (CCI) is an umbrella organization currently representing 180 parent-led childhood cancer organizations in 90 countries. Today CCI has launched child4Child.com, the first global initiative where their member organizations join forces to raise awareness of childhood cancer. Of the 250,000 children that are diagnosed with cancer each year, about 90,000 of them will lose their lives to the disease, making cancer the number one non-communicable disease-related cause of death of children worldwide. The organization has now teamed up with some of the most talented singing kids on YouTube, many of them famous for their appearances on talent shows such as America’s Got Talent, The Voice Kids Australia and Britain’s Got Talent. Their performances have together reached over 300 million views on YouTube.

The new song “We Are One” is written by internationally acclaimed composer Christophe Beck, most known for creating the score to Disney’s smash hit Frozen.

“I’ve composed the scores to over a hundred films, including Hollywood blockbusters such as The Hangover, Ant-Man, and The Peanuts Movie. But this has by far been one of my most challenging assignments. Luckily I had my daughter Sophie by my side, a talented and precocious musician and songwriter herself, along with lyricist David Goldsmith, who wrote some beautiful words to inspire us. The three of us have been working on the song together and I am extraordinarily pleased with the results,” says Christophe Beck.

Children are invited to sing and record the chorus of the song on the child4child.com website starting January 11th. One month later on February 15th, the International Childhood Cancer Day, the song will be released on music streaming platforms such as Spotify and iTunes. The chorus of the song will contain all voices recorded on the website.

“With the song ”We Are One” we wish to honor all children of the world, particularly those in their courageous battle against cancer,” says Carmen Auste, the current Chair of CCI and the mother of a childhood cancer survivor.

Child Ambassadors for the campaign are Alexa Curtis (winner of The Voice Kids Australia 2014, Livvy Stubenrauch (the voice of Anna in Disney’s Frozen), Robbie Firmin (Britain’s Got Talent) and Aaralyn O’Neil (America’s Got Talent).

 

Children from around the world can visit the website from January 11th until early February. Then on February 15th, International Childhood Cancer Day, the chorus version of all of the children who had recorded themselves singing will be launched on global music platforms.

A music video will also be released on YouTube with clips of the children who have helped record the chorus.
Join the chorus of children around the world in solidarity with those battling cancer.

We are one.

We are strong.

And we will sing this song together

So sing along

And as one

We will rise

We won’t give up the fight until the night

Yields to the sun

We are one.

Two MEPs join the fight

On November 10th, 2015 Françoise Grossetête and Glenis Willmott, MEPs highly involved in the cause of children with cancer for many years, joined with Unite2Cure to CALL FOR IMMEDIATE ACTION to give more children and adolescents the prospect of a better life.

Their letter to Mr. Andriukaitis, Commissioner for Health and Food Safety, requests that the Commission immediately evaluate the situation and the application of the Paediatric Regulation, in order to be able to correct it as soon as possible.

As they state in their letter, today in Europe, children with cancer and other life-threatening diseases are being denied access to potentially life-saving treatments. This is a public health issue of prime importance. Cancer is the leading cause of death by disease in children across EuropeEach year, 35,000 children and adolescents are diagnosed with leukaemia or malignant solid tumours and 6000 of them die. Of the survivors, 40% will be left with severe long term side-effects which impact their daily life. For some conditions with a poor prognosis, only very limited improvements in treatments for children have been seen in recent decades.

The time for action is NOW.

To read the full letter to Commissioner Andriukaitis, click here

 

Taking care of business

Chris heads to the headquarters of the European Medicines Agency on behalf of Unite2Cure…

The brash banking centre of Canary Wharf, with its gleaming sky-high towers, is the unlikely location for the headquarters of that most decorous of institutions, the European Medicines Agency.  Standing between the murky waters of the Thames and Barclays HQ, the EMA gleams like a beacon for health rather than wealth, right in the heart of London’s bonus-driven business district.

The business I was to witness there, though, was of an altogether different kind.

Continue reading…

A response to our article

On November 23rd, Unite2Cure posted an article entitled We need to move the lines, which was our message to the European Commission. Written by Chris Copland on behalf of Unite2Cure, the letter was addressed to Ms Juelicher, who is Head of Unit, Medicinal Products – Authorisations, European Medicines Agency, as well as to Commissioner Andriukaitis, Commissioner for Health and Food Safety, European Commission.

In it we describe how we found the Commission’s position, that the concerns raised by Mrs Wilmott and Mme Grossetete during the  ‘Exchange of Views with the European Commission and EMA on the Policy on the Conditions for a Paediatric Investigation Plan/Waiver.’  on November 10, should be put aside until 2017, a sadly complacent one.

On December 17th we received a reply. Unfortunately, it does not address our concerns but is simply a copy of a letter sent to Mrs Wilmott and Mme Grossetete. We are disappointed in this response.

Response from Ms. Jülicher

Reply to Ms Grossetête and Ms Willmott,

We have replied to their letter as follows and hope to hear more soon.

 

Dear Ms Julicher

Thank you for your response to our message. We were, however, disappointed that you simply referred to your open letter to Ms Wilmott, MEP and did not provide us with a direct reply.  Although the letter was on associated themes, it did not address specific points we had made, for example about orphan illnesses. We, however, would like to respond here to the points you made, in particular your assessment of whether the Paediatric Regulation is functioning as effectively as it might.

As you point out, what makes the Paediatric Regulation different is that it does not just offer incentives, it places a requirement on companies to conduct studies into children. The effectiveness of this approach has been demonstrated in recent years but, unfortunately, it has not achieved its potential with regard to the most deadly of young people’s illnesses cancer.

You assert that the Regulation allows companies to propose paediatric plans for cancer on their own initiative, and it is true that on occasion this has happened. However, the track record, over decades, of companies voluntarily engaging with paediatric research is not an encouraging one (see Raymond and Herold). On the other hand, their willingness to avoid requirements by resorting to the loophole of the waiver system has been clearly demonstrated. As has been frequently related, during the first five years of the Regulation, over half of the adult drugs with a significant potential for children’s cancers had waivers requested and granted (see Vassal below).

You paint a positive picture by referring to the recent statistics supplied to you by the EMA. As we have not seen this data, we cannot respond to your interpretation in detail. However, we note that you place emphasis on the number of programmes that ‘target a condition where most patients are in the paediatric age range.’ You do not clarify whether, in these cases, a PIP has proceeded because there is a common condition for both adult and child or because companies have simply opted not to apply for a waiver. Either way, this ignores the simple fact that ‘’PDCO has to grant a waiver if the disease only occurs in adults.’ (EMA)

This is the central weakness of the legislation with regard to cancer, a disease which manifests itself differently in adults and children but still derives from a common biology. As Gilles Vassal has reported, 90% of the drugs successfully given to young people with cancer over the past 40 years have been used with different tumour types in adults. Ultimately, the legislation can only be made consistent and genuinely productive by basing the requirement to produce a Paediatric Investigation Plan on the biology that underlies adult cancers rather than simply the tumour type.

We acknowledge that some companies may conduct a PIP they are not required to and which may involve pursuing the mechanism of action. This may be the result of altruism or, more likely, because of the incentives the legislation offers. However, this is unlikely to generate research in anything more than a haphazard fashion. As parents, we expect industry to conduct paediatric research systematically and as a matter of course – our children deserve no less. This is why the Paediatric Regulation’s emphasis on requirements, which you yourself accept is what makes it different, is so important. The point is such obligations must be applied consistently and correspond with our current understanding of biological science.

It is of course heartening to read of the oncology PIPs currently proceeding, but, after ten years, these are still in relatively small numbers when one considers the scale of the problem to be overcome – 6,000 deaths of young people in Europe every year from cancer.

The urgency of the situation is distilled in the words of one parent:

‘It is inconceivable in this day and age that, globally, there is no drug that can cure my daughter’

This is the view of the nearly 1500 people who have signed our petition and of the many prominent professionals and associations (SIOPE included) that have come out in our support. If one reads the literature, there is a clear consensus in the professional community of the changes that are necessary to put the regulation on track and of the urgency of doing so. As members of the CDDF ITCC ENCCA SIOPE Paediatric Platform concluded at our conference this time last year: Waiting is not an option.

We look forward to a productive engagement with ENVI in the New Year. In the meantime, may we wish you and your staff a Happy Christmas.

Regards,

Christopher Copland

on behalf of Unite2Cure